BC
BEAM icon

Bayforest Capital’s Beam Therapeutics BEAM Stock Holding History

Bayforest Capital’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$369K Buy
+10,740
New +$324K 0.34% 28
2025
Q4 		– Sell
-4,682
Closed -$114K – 801
2025
Q3 		$114K Buy
+4,682
New +$93.1K 0.05% 499

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Bayforest Capital's BEAM Position: Q2 2026 in Review

Bayforest Capital opened a new position in Beam Therapeutics (BEAM) in Q2 2026: 10,740 shares worth $369K. The stake represents 0.34% of the portfolio and ranks #28 among its holdings. This is a return to the name: Bayforest Capital previously reported a position in BEAM as recently as Q3 2025.

Bayforest Capital first reported a position in BEAM in Q3 2025 and has held it in 2 quarters since. 278 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • Bayforest Capital held 10,740 shares of Beam Therapeutics worth $369K as of Q2 2026.
  • Beam Therapeutics was a new Bayforest Capital position in Q2 2026.
  • Beam Therapeutics made up 0.34% of Bayforest Capital's portfolio in Q2 2026, its #28 holding.
  • Bayforest Capital first reported a position in Beam Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • 278 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Bayforest Capital's 13F filing for Q2 2026, filed 5 Aug 2026.